Flexion’s FX006 Demonstrates Superior Pain Relief Compared to Standard-of-Care in Phase 2b Osteoarthritis Trial

by admin on June 26, 2013

BURLINGTON, Mass., June 26, 2013 /PRNewswire/ –  Flexion Therapeutics , Inc., today reported that its lead compound FX006, a novel intra-articular (IA), sustained release steroid, demonstrated pain relief …

View full post on pain – Yahoo! News Search Results

Previous post:

Next post: